Covance, Inc. (NYSE:CVD)

CAPS Rating: 4 out of 5

A drug development services company providing a range of early stage and late stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries.

Recs

0
Player Avatar NRT104 (< 20) Submitted: 8/9/2009 9:22:24 AM : Outperform Start Price: $54.72 CVD Score: -46.69

drus will go up

Report this Post Reply

Featured Broker Partners


Advertisement